Back to Rare Disease
This trial is complete. It is no longer accepting participants.

NCT00004654

NCT00004654
Completed Phase 3

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT), a condition affecting blood vessels, AND have at least 2 of the following: a close family member (parent, sibling, or child) with HHT; a history of recurring nosebleeds or bleeding in the digestive system; three or more small red spots on the skin caused by widened blood vessels
  • You experience migraine headaches at least 3 times a month, and have done so for more than 1 year
  • Your migraines meet specific recognised diagnostic standards set by the International Headache Society (confirm with trial site)
  • It has been at least 1 month since you last took any medication specifically to prevent migraines
  • It has been at least 1 month since you last took any of the following types of medication: beta blockers, calcium channel blockers, divalproex sodium, tricyclic antidepressants, or SSRIs (a type of antidepressant)
  • You are currently taking regular treatment for migraines and/or digestive bleeding (this is allowed)
  • Your kidney function is within an acceptable range, based on a blood test result (confirm with trial site)

Who may not be able to join:

  • You have headaches every single day as a regular pattern
  • You have experienced a serious head injury
  • Your headaches first started after you were 50 years old
  • You have an allergy to soy
  • You are currently pregnant
  • You are planning to become pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
National Center for Research Resources (NCRR)
Registry
clinicaltrials_gov
Start date
1 January 1996

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov